Lotenib Capsule 100 mg contains Larotrectinib, a targeted oncology medication used for the treatment of certain solid tumors driven by specific genetic changes. Larotrectinib represents an advanced form of precision cancer therapy, meaning it targets cancer cells based on genetic abnormalities rather than the tumor’s location in the body. Specifically, it is prescribed for tumors that exhibit a neurotrophic receptor tyrosine kinase (NTRK) gene fusion, a rare genetic mutation found in a variety of adult and pediatric cancers.

This oral capsule is designed to be taken regularly over an extended period, providing continuous suppression of cancer growth by interfering with key cellular pathways that drive tumor survival.

রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Mechanism of Action

Larotrectinib works as a TRK inhibitor — it targets tropomyosin receptor kinases (TRKA, TRKB, and TRKC), which are proteins produced by the NTRK1, NTRK2, or NTRK3 genes. Some cancers form fusion proteins when these genes are abnormally rearranged with other gene partners. These TRK fusion proteins become constantly active and drive cancer growth and survival. Larotrectinib selectively binds and inhibits these aberrant TRK proteins, blocking the signaling pathways that fuel tumor cell proliferation and survival.

This gene‑fusion‑targeted approach allows Larotrectinib to be effective across multiple types of solid tumors, irrespective of the tissue of origin, as long as the tumor contains an NTRK fusion.

Indications

Lotenib Capsule 100 mg is indicated for:

• Adult and pediatric patients with solid tumors that have an NTRK gene fusion without a known resistance mutation.

• Metastatic or unresectable tumors where surgery is likely to cause severe morbidity.

• Tumors that have progressed after other therapies or for which no satisfactory alternative treatments are available.

This makes Larotrectinib a tumor‑agnostic therapy — its use is based on the tumor’s genetic profile, not just its anatomical site.

Dosage and Administration

• The usual adult dosage is 100 mg orally twice daily, with or without food, continued until disease progression or unacceptable toxicity.

• For pediatric patients with smaller body size, dosing is adjusted by body surface area (BSA) — typically 100 mg/m² twice daily.

• Capsules should be swallowed whole with a glass of water; they should not be chewed or crushed.

• If a dose is missed, do not take an extra dose within six hours of the next scheduled administration.

Precautions

Before taking Lotenib Capsule:

• Inform your doctor about other medications you are taking, especially those affecting CYP3A4 enzymes, as Larotrectinib is metabolized through this pathway. Strong CYP3A4 inhibitors (e.g., certain antifungals or grapefruit products) can increase levels of Larotrectinib, while inducers (e.g., rifampin or St. John’s wort) can decrease its effectiveness.

• Liver function and blood tests should be monitored regularly during therapy to identify early signs of liver toxicity or blood abnormalities.

• Discuss pregnancy status before treatment, as effects on a developing fetus are uncertain and targeted oncology agents are typically avoided unless essential.

  রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Possible Side Effects

Common side effects reported with Larotrectinib include:

• Nausea, vomiting, diarrhea, constipation

• Fatigue and dizziness

• Headache

• Cough and respiratory symptoms

• Elevated liver enzymes (AST, ALT)

• Blood cell changes, such as anemia or neutropenia

• Appetite changes and weight gain

• Skin rash and joint or muscle pain

Less common but serious effects can include hepatotoxicity (liver injury), neurocognitive symptoms (e.g., confusion or memory changes), and immune or bone complications. Immediate medical attention is advised if severe symptoms occur.

Storage

Store Lotenib Capsule 100 mg at room temperature, away from moisture and heat, and keep out of reach of children.

Lotenib Capsule 100 mg offers a targeted therapeutic option for patients with NTRK fusion‑positive solid tumors, providing a personalized approach to cancer treatment by directly inhibiting the genetic drivers of tumor growth.